Skip to content

Excellus BCBS

Does Excellus BCBS cover Wegovy?

Yes. Excellus BCBS covers Wegovy for weight loss with prior authorization if your BMI is 40 or higher, or 35 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Adult weight loss — Class III obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 40 kg/m² (Class III obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)

Adult weight loss — Class II obesity with comorbidity

All of:

  • Age ≥ 18 years
  • BMI 35–39.9 kg/m² (Class II obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)

Plus any one of:

  • Cardiovascular Disease
  • Dyslipidemia (high LDL, TG, or low HDL)
  • Gallstones
  • Gynecological abnormalities
  • Hypercholesterolemia
  • Hypertension
  • Metabolic Syndrome
  • MAFLD
  • Pulmonary Hypoventilation
  • Obstructive Sleep Apnea
  • Stress Incontinence
  • Type 2 Diabetes
  • Weight-Bearing Joint Arthropathy

Adolescent weight loss (ages 12–17)

All of:

  • Age 12–17 years
  • BMI ≥ 95th percentile standardized for age and sex
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Wegovy tablets and Wegovy HD 7.2mg injection NOT approved for adolescents
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist

Documentation to bring

  • Baseline BMI and weight documentation
  • Height documentation
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of current and prior participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Progress notes documenting clinical status at time drug was originally initiated (weight, height, BMI, comorbid conditions)
  • For adolescents: BMI percentile ≥95th for age and sex documentation

Quantity limits

  • 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, 7.2mg (Wegovy HD) — 4 pens per 28 days; requests outside this limit not approved; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; first 3 fills of Wegovy HD 7.2mg limited to 28-day supply or less (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days; first 6 fills for new starts limited to 30-day supply or less (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • Renewal: At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (1.7mg, 2.4mg, or 7.2mg injection OR 25mg tablet). Continued comprehensive weight management program enrollment required (provider acknowledgement via PA form or progress note). Wegovy HD 7.2mg only for patients who tolerated 2.4mg for ≥4 weeks and clinically require additional weight loss.
  • Renewal: At least 17 weeks on therapy before the first renewal.
  • Renewal: Staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Non-FDA approved diagnoses not covered
  • Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
  • Organic causes of obesity (e.g., hypothyroidism) must be excluded before prescribing
  • Ozempic (semaglutide) will not be authorized at doses >2mg once weekly (active weight management formulation Wegovy exists)
  • Demonstration of failed efficacy (not meeting continuation criteria) precludes future coverage of same drug

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: BMI thresholds may be adjusted for ethnicity on a case-by-case basis; Asian population: BMI ≥25 kg/m² suggests clinical obesity and consideration for pharmacological treatment. Documentation must reflect patient's clinical status at time drug was originally initiated, regardless of date of current coverage request. Patients not treated in past 4 months considered new to therapy. Wegovy HD 7.2mg only indicated for patients who tolerated 2.4mg for ≥4 weeks and clinically require additional weight loss. 0.25mg, 0.5mg, and 1mg injection and 1.5mg, 4mg, 9mg tablet dosages are initiation/escalation doses only, not approved as maintenance. Annual day-supply limits apply cumulatively across all GLP-1/GIP-GLP-1 products.

verified June 5, 2026 · source: Weight Management Policy Pdf · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

CV risk reduction — established cardiovascular disease without diabetes

All of:

  • Age ≥ 18 years
  • BMI ≥ 27 kg/m²
  • Wegovy prescribed by or in consultation with a cardiologist or neurologist (prescriber attestation required)
  • Established cardiovascular disease (prior MI, prior stroke, symptomatic PAD with ABI <0.85, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease) documented via progress notes
  • Currently a non-smoker (not smoked in past 6 months)
  • Partaking in a heart healthy diet
  • Engaging in physical activity at level of ability
  • Commitment to continue lifestyle modifications while on Wegovy
  • Optimized on standard of care treatment for prevention of secondary cardiovascular events per prescriber (may include lipid-lowering, blood pressure-lowering, SGLT2i when appropriate, antiplatelet when appropriate)
  • No diagnosis of diabetes mellitus
  • No diagnosis of end-stage renal disease
  • No NYHA Class IV heart failure symptoms
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with any weight loss drugs (Rx, OTC, or herbal)

Documentation to bring

  • Baseline BMI documentation (≥27 kg/m²)
  • Progress notes demonstrating established CVD (prior MI, prior stroke, symptomatic PAD with ABI <0.85, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease)
  • Prescriber attestation that Wegovy is prescribed by or in consultation with a cardiologist or neurologist
  • Documentation that patient is currently a non-smoker (not smoked in past 6 months)
  • Documentation that patient is partaking in a heart healthy diet
  • Documentation that patient is engaging in physical activity at their level of ability
  • Documentation of patient commitment to continue lifestyle modifications while on Wegovy
  • Documentation that patient is optimized on standard of care for secondary CVD prevention (lipid-lowering, blood-pressure-lowering, SGLT2i when appropriate, antiplatelet when appropriate)
  • Documentation that patient has no diagnosis of diabetes mellitus, ESRD, or NYHA Class IV heart failure
  • At recertification: documentation of ≥80% PDC since last approval
  • At recertification: documentation of continued non-smoker status, heart-healthy diet, and physical activity

Quantity limits

  • 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg — 4 pens per 28 days (Wegovy HD 7.2mg NOT approved for CV risk reduction indication); Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • Renewal: Upon recertification: patient must be utilizing 2.4mg OR 1.7mg injection OR 25mg tablet as maintenance dose; must demonstrate ≥80% PDC (Percent Days Covered) since last approval; must still be a non-smoker, partaking in a heart healthy diet and engaging in physical activity; must not have developed type 2 diabetes, ESRD, or NYHA Class IV heart failure symptoms. Note: GDMT optimization and CVD diagnosis are not explicitly re-verified at continuation per policy text.
  • Renewal: At least 17 weeks on therapy before the first renewal.
  • Renewal: Staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Diabetes mellitus diagnosis excludes from this indication (consider GLP-1 agonists FDA-approved for CV risk reduction in T2DM instead)
  • End-stage renal disease diagnosis excludes from this indication
  • NYHA Class IV heart failure symptoms exclude from this indication
  • Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Combination with any weight loss drugs (Rx, OTC, or herbal) not approved
  • Wegovy HD 7.2mg not approved for this indication

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: Standards of care for secondary CVD prevention may include lipid-lowering therapies, blood pressure-lowering therapy, SGLT2 inhibitors when appropriate, and antiplatelet therapy when appropriate — prescriber determines optimization. Wegovy HD 7.2mg explicitly NOT approved for this indication. For patients with type 2 diabetes seeking CV risk reduction, policy directs to GLP-1 agonists FDA-approved for MACE reduction in T2DM. BMI thresholds may be adjusted for Asian population (≥25 kg/m² suggests clinical obesity) on case-by-case basis. Annual GLP-1 day-supply limits apply cumulatively across all products.

verified June 5, 2026 · source: Weight Management Policy Pdf · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH with moderate-to-advanced fibrosis — BMI ≥35 with MAFLD/MASH comorbidity

All of:

  • Age ≥ 18 years
  • Noncirrhotic MASH with moderate to advanced liver fibrosis (F2–F3 fibrosis)
  • BMI ≥ 35 kg/m² with qualifying comorbidity (MAFLD/MASH qualifies)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)

Documentation to bring

  • Baseline BMI documentation (≥35 kg/m²)
  • Documentation of noncirrhotic MASH with F2–F3 fibrosis
  • Documentation of MAFLD/MASH as qualifying comorbidity
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo

Quantity limits

  • 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, 7.2mg (Wegovy HD) — 4 pens per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days; first 6 fills for new starts limited to 30-day supply or less (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • Renewal: Continuation criteria follow existing weight management policy: ≥5% weight loss by 7 months, maintained ≥5% weight loss or continued weight loss at subsequent recertifications, BMI not less than 18.5 kg/m², and maintenance dose (1.7mg, 2.4mg, or 7.2mg injection OR 25mg tablet). MASH fibrosis staging not re-verified at continuation per policy structure.
  • Renewal: At least 17 weeks on therapy before the first renewal.
  • Renewal: Staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • BMI < 35 kg/m² considered not medically necessary for MASH even in presence of MAFLD/MASH — insufficient evidence of efficacy in non-obese/overweight population
  • Cirrhotic MASH not covered (noncirrhotic only)
  • Combination with other GIP and/or GLP-1 receptor agonists not approved
  • Combination with other weight loss drugs (Rx, OTC, or herbal) not approved
  • MASH indication approved under FDA accelerated approval — continued approval contingent upon verification of clinical benefit in confirmatory trial

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: FDA approved Wegovy injection for noncirrhotic MASH with moderate to advanced fibrosis (F2–F3) on August 15, 2025, under accelerated approval. Policy restricts coverage to patients with BMI ≥35 kg/m² by integrating MASH into existing weight management criteria (Class II obesity with MAFLD/MASH comorbidity). Policy explicitly states BMI <35 is not medically necessary citing: <3% of ESSENCE trial participants had BMI <27, mean trial BMI was 34.6, subgroup efficacy in non-obese/overweight not established, primary outcomes were biopsy-confirmed (not hard outcomes), long-term outcomes data expected 2029, and histologic improvements strongly correlate with weight reduction. No specific MASH confirmation method (FIB-4, FibroScan, biopsy, MRE, ELF) is specified in this policy — policy references FDA approval criteria of F2–F3 fibrosis only.

verified June 5, 2026 · source: Weight Management Policy Pdf · View policy document (PDF)

Open on its own page →

Questions people ask
Does Excellus BCBS cover Wegovy?
Yes. Excellus BCBS covers Wegovy for weight loss with prior authorization if your BMI is 40 or higher, or 35 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with Excellus BCBS?
Weight Loss — Applies to Employer and ACA Marketplace plans. Initial approval: 7 months. Renewal: every 6 months. Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. Initial approval: 7 months. Renewal: every 6 months. Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Initial approval: 7 months. Renewal: every 6 months.
What does Excellus BCBS require to renew Wegovy?
Weight Loss — Applies to Employer and ACA Marketplace plans. At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (1.7mg, 2.4mg, or 7.2mg injection OR 25mg tablet). Continued comprehensive weight management program enrollment required (provider acknowledgement via PA form or progress note). Wegovy HD 7.2mg only for patients who tolerated 2.4mg for ≥4 weeks and clinically require additional weight loss. At least 17 weeks on therapy before the first renewal. Staying on a maintenance dose of at least 1.7 mg. Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. Upon recertification: patient must be utilizing 2.4mg OR 1.7mg injection OR 25mg tablet as maintenance dose; must demonstrate ≥80% PDC (Percent Days Covered) since last approval; must still be a non-smoker, partaking in a heart healthy diet and engaging in physical activity; must not have developed type 2 diabetes, ESRD, or NYHA Class IV heart failure symptoms. Note: GDMT optimization and CVD diagnosis are not explicitly re-verified at continuation per policy text. At least 17 weeks on therapy before the first renewal. Staying on a maintenance dose of at least 1.7 mg. Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Continuation criteria follow existing weight management policy: ≥5% weight loss by 7 months, maintained ≥5% weight loss or continued weight loss at subsequent recertifications, BMI not less than 18.5 kg/m², and maintenance dose (1.7mg, 2.4mg, or 7.2mg injection OR 25mg tablet). MASH fibrosis staging not re-verified at continuation per policy structure. At least 17 weeks on therapy before the first renewal. Staying on a maintenance dose of at least 1.7 mg.
How current is this information?
The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Excellus BCBS: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Elevance Health, EmblemHealth, Highmark, Independent Health, Molina Healthcare, New York Medicaid, BCBS Alabama, BCBS Arizona

All insurance plans · All medications

Summary of Excellus BCBS's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.